Oral News and Research

RSS

Live zoster vaccine associated with reduced risk of HZ in patients with immune-mediated diseases

Although some have suggested that patients receiving medication for immune-mediated diseases such as rheumatoid arthritis or psoriasis may be at increased risk of herpes zoster (HZ; shingles) shortly after receipt of the vaccine, an analysis that included nearly 20,000 vaccinated Medicare beneficiaries finds that the live zoster vaccine is not associated with an increased risk of HZ shortly after vaccination in patients currently treated with biologics, and that it is associated with a significantly reduced longer-term risk of HZ in patients with an immune-mediated disease, according to a study in the July 4 issue of JAMA.

4 Jul 2012

UCLA School of Dentistry receives NIH grant to create comprehensive research training program

In recent years, faculty at the UCLA School of Dentistry have been expanding the traditional boundaries of dentistry through groundbreaking multidisciplinary research that has led to major advances in everything from stem cell science to saliva diagnostics. Now, a $5 million grant from the National Institutes of Health's National Institute of Dental and Craniofacial Research will allow the school to continue these pioneering efforts by creating a comprehensive research training program to help cultivate the next generation of dentist-scientists and oral health researchers.

4 Jul 2012

Polio elimination hindered by unvaccinated children in Pakistan and Afghanistan

Too few children have received sufficient doses of vaccine to wipe out polio in Pakistan and Afghanistan, two of only three countries in the world where endemic polio has yet to be eliminated, according to new research published Online First in The Lancet. The findings suggest that the newly introduced bivalent oral poliovirus vaccine (OPV) has the potential to eliminate polio in these countries if sufficient numbers of children could be reached by vaccination programmes.

4 Jul 2012

OraSure Technologies receives FDA approval for new in-home HIV test

The U.S. Food and Drug Administration today approved the OraQuick In-Home HIV Test, the first over-the-counter, self-administered HIV test kit to detect the presence of antibodies to human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2).

4 Jul 2012

FDA approves Lupin’s Norgestimate and Ethinyl Estradiol Tablets

Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. has received approval for its Norgestimate and Ethinyl Estradiol Tablets, 0.18 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.25 mg/0.025 mg from the United States Food and Drugs Administration (FDA).

4 Jul 2012

Treating Sickle Cell Disease with L-Glutamine

By focusing on how best to help patients, researchers can sometimes find solutions that are much simpler than anticipated. That has been the guiding approach to our efforts to develop a treatment for sickle cell disease.

3 Jul 2012

CBS News: Roberts shifted view on constitutionality of individual mandate

CBS News reports that Supreme Court Chief Justice John Roberts Jr. initially sided with conservatives before he changed his mind and formed an alliance with liberals to uphold most of the health care law. Other news outlets scrutinize Roberts's historic decision.

3 Jul 2012

Three-step clinical pathway for CAP reduces length of hospital stay

A three-step pathway helps to reduce the duration of intravenous antibiotic treatment in hospitalized patients with community-acquired pneumonia, show study findings published in the Archives of Internal Medicine.

2 Jul 2012

Janssen seeks accelerated FDA approval for bedaquiline to treat MDR-TB

Janssen Research & Development, LLC today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the use of the investigational drug bedaquiline (TMC207) as an oral treatment, to be used as part of combination therapy for pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults.

2 Jul 2012

Clinical results for Teva's biologic oncology candidates presented at MASCC/ISOO 2012

Teva Pharmaceutical Industries Ltd. announced today the presentation of clinical results for its biologic oncology candidates, lipegfilgrastim and balugrastim, at the Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) 2012 International Symposium on Supportive Care in Cancer being held in New York June 28-30.

2 Jul 2012

How the High Court's decision contributes to Obama's legacy

News outlets report on how the health law, and the Supreme Court's review of it, will be important parts of President Barack Obama's place in history.

30 Jun 2012

Eight-year trends in pediatric drug use examined

A review of US outpatient pediatric drug use over the past 8 years shows a decrease in systemic antibiotic, allergy, pain, and depression prescriptions, and an increase in asthma, attention deficit/hyperactivity disorder, and contraceptive prescriptions.

29 Jun 2012

Liraglutide efficacy in Japanese patients “easy” to predict

Liraglutide therapy is an effective alternative to basal-supported oral therapy for some Japanese patients with diabetes, while it is completely ineffective for others, report researchers.

29 Jun 2012

A.P. Pharma announces additional data from APF530 Phase 3 study on CINV

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced additional data from the Company's Phase 3 study of APF530 for the prevention of chemotherapy-induced nausea and vomiting (CINV).

29 Jun 2012

Lexicon announces results from two initial trials of LX4211 for type 2 diabetes

Lexicon Pharmaceuticals, Inc. announced today the publication of results from two initial trials of LX4211 in patients with type 2 diabetes in the online edition of the journal Clinical Pharmacology & Therapeutics.

29 Jun 2012

RapidChek- SELECT Salmonella highly sensitive to the presence of S. Typhi vaccine in stool

Salmonella Typhi (S. Typhi) is the causative agent of typhoid fever, a serious health threat resulting in some 22 million new cases yearly and approximately 217,000 fatalities. A number of novel vaccine candidates using live attenuated strains of Salmonella are being developed, but care must be taken to ensure the bacteria are not excreted into the environment following vaccination.

29 Jun 2012

Bayer receives priority review designation from FDA for regorafenib NDA

Bayer HealthCare and Onyx Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted priority review designation to Bayer HealthCare's New Drug Application (NDA) filed end of April 2012 for the oral multi-kinase inhibitor regorafenib, for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.

29 Jun 2012

Results from Access’ MuGard Phase 4 trial on oral mucositis

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company developing treatments in areas of oncology and oncology supportive care, announced that Dr. Ron R. Allison of Carolina Radiation Medicine, Greenville, NC, presented results from its ongoing MuGard Phase 4 clinical trial in oral mucositis (OM) at the Multinational Association of Supportive Care in Cancer (MASCC) Conference in New York City.

29 Jun 2012

Oral health may be linked to HPV status of head and neck cancer

The chronic oral inflammatory disease periodontitis may be associated with human papillomavirus status in individuals with head and neck squamous cell carcinoma, report researchers.

28 Jun 2012

Data from Infinity’s IPI-145 pre-clinical study on inflammatory diseases

Infinity Pharmaceuticals, Inc. today reported preclinical data for IPI-145, the company's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The data demonstrate potent PI3K-delta and -gamma inhibition in biochemical, cellular and whole blood assays and activity in multiple preclinical models of inflammatory disease, including rheumatoid arthritis and asthma.

28 Jun 2012